Craft

Biofrontera US

Stock Price

$0.9

2024-10-29

Market Capitalization

$5.1 M

2024-10-29

Revenue

$41.7 M

FY, 2025

Biofrontera US Summary

Company Summary

Overview
Biofrontera US is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions caused primarily by exposure to sunlight. It offers Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis; BF-RhodoLED lamp, photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis, and Belixos, an over-the-counter line of skin care cosmetic products.
Type
Public
Status
Active
Founded
2015
HQ
Woburn, MA, US | view all locations
Website
https://www.biofrontera-us.com/
Cybersecurity rating
Sectors

Key People

  • Daniel Hakansson

    Daniel Hakansson, General Counsel and Head of Compliance

LocationsView all

1 location detected

  • Woburn, MA HQ

    United States

    120 Presidential Way, Suite 330

Biofrontera US Financials

Summary Financials

Revenue (Q1, 2026)
$10.1M
Gross profit (Q1, 2026)
$9.5M
Net income (Q1, 2026)
($4.8M)
Cash (Q1, 2026)
$6.3M
EBIT (Q1, 2026)
($4.3M)
Enterprise value
$1.8M

Footer menu